FDA Approves Relacorilant Combination Therapy for Platinum-Resistant Ovarian Cancer On March 25, 2026, the Food and Drug Administration (FDA) approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a first-in-class selective glucocorticoid receptor …
Tag: